Episode 304: A PSMA CD3 Bispecific T-cell Engager in CRPC

Dr. Tanya Dorff joins the podcast to discuss her work on a phase 1 study investigating acapatamab, a CD3 and PSMA bispecific t-cell engaging antibody studied in advanced prostate cancer.

Dr. Dorff is an associate professor of medical oncology and therapeutics research, and serves as the section chief of the Genitourinary Disease Program at City of Hope.